Biotech and StockMarket Podcast May 31 2016… $IONS $RLYP Gold, Oil + Macros $IONs discussed here on why we took call options. Danny explains the situation there and why it’s not as bad as the market is thinking. We also…
Tag: small cap biopharma
Why This Small Cap Biotech Is Likely To Rally Soon
In small cap developmental biotech, we see a lot of creative financing, and when we understand how it works, we can profit from it. These types of biotech charts normally trade in a consistent ‘channel pattern.’ and when we spot…
Important Upcoming Catalyst For Antares – FDA Decision Expected October 14
n a bit more deliberate than Jazz, but is coming along nicely. Antares started its royalty deals with a gel based platform, one being a royalty deal with Actavis, Inc. (NYSE: ACT) (formely Watson Pharma) for topical oxybutynin gel. Oxybutynin…
Significant Near Term Catalyst Should Further Rally Keryx Pharmaceuticals
Recently, we have detailed companies that have released positive Phase III data because we believe several of these companies continue to be under speculation value. Companies who have strong management, cash, and a strong pipeline can be very profitable for…
Wednesday’s Biotech Catalyst Trade Watch List
Today, I list four biotech companies with significant near-term catalysts ahead. Under normal market conditions, these stocks should see decent to very strong appreciation in the short-term. There are various ways to play these catalyst trades. Traders and investors can…
Trius and General Market Commentary 6/5/13
Trius and General Market Commentary 6/5/13.. Answering critics and explaining market cap to price. Business basics as well.
Trius Therapeutics: The Next Big Small-Cap Biotech Mover?
Normally, I write about biotech companies with near-term catalysts I feel offer traders good long based trade opportunities heading into these catalysts. Every so often, I find a small cap biotech where I feel a speculation investment is truly warranted.…
Video Chart Analysis and Commentary on Trius Therapeutics ($TSRX)
Video Chart analysis and commentary onĀ Trius Therapeutics (TSRX). From the Aegis analyst report, we read the following: In the wake of this data, we are raising our probability of success for tedizolid from 60% to 80%, which increases the…
BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market
These days, prescription drugs have become a source for legal and illegal abuse. This abuse can lead to a medical diagnosis called opioid dependence, which is when a patient that is addicted to opioids such as morphine, hydrocodone, oxycodone, or…
Insmed Chart technicals with my opinion and explanation: YouTube Video
Insmed Chart technicals with my opinion and explanation: YouTube Video below, enjoy!